Automatic three-year exclusivity for Rx-to-OTC switches urged by NDMA.
This article was originally published in The Tan Sheet
Rx-TO-OTC SWITCHES AUTOMATIC THREE-YEAR EXCLUSIVITY URGED BY NDMA in written comments to the April 11 Senate Labor & Human Resources Committee hearing on FDA reform ("The Tan Sheet" April 14, p. 15). Among its requests, the Nonprescription Drug Manufacturers Association asks for a congressional "declaration that the grant of three-year exclusivity in current law shall be the general rule for applications to switch a drug from prescription to nonprescription status, to ensure the continued vitality of the important OTC switch movement."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC